Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.

Portaccio E, Annovazzi P, Ghezzi A, Zaffaroni M, Moiola L, Martinelli V, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Patti F, Solaro C, Bellantonio P, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.

Neurology. 2018 Mar 6;90(10):e823-e831. doi: 10.1212/WNL.0000000000005067. Epub 2018 Feb 7.

PMID:
29438046
2.

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.

Portaccio E, Moiola L, Martinelli V, Annovazzi P, Ghezzi A, Zaffaroni M, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Solaro C, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.

Neurology. 2018 Mar 6;90(10):e832-e839. doi: 10.1212/WNL.0000000000005068. Epub 2018 Feb 7.

PMID:
29438041
3.

Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort.

Manni A, Direnzo V, Iaffaldano A, Di Lecce V, Tortorella C, Zoccolella S, Iaffaldano P, Trojano M, Paolicelli D.

Brain Behav. 2017 Aug 29;7(10):e00804. doi: 10.1002/brb3.804. eCollection 2017 Oct.

4.

A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-β1a using RebiSmart™-the FUTURE study.

Ghezzi A, Bianchi A, Baroncini D, Bertolotto A, Malucchi S, Bresciamorra V, Lanzillo R, Milani N, Martinelli V, Patti F, Chisari C, Rottoli M, Simone M, Paolicelli D, Visconti A; FUTURE Study Group.

Neurol Sci. 2017 Nov;38(11):1999-2005. doi: 10.1007/s10072-017-3091-6. Epub 2017 Aug 22.

PMID:
28831635
5.

Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study).

Messina S, Solaro C, Righini I, Bergamaschi R, Bonavita S, Bossio RB, Brescia Morra V, Costantino G, Cavalla P, Centonze D, Comi G, Cottone S, Danni MC, Francia A, Gajofatto A, Gasperini C, Zaffaroni M, Petrucci L, Signoriello E, Maniscalco GT, Spinicci G, Matta M, Mirabella M, Pedà G, Castelli L, Rovaris M, Sessa E, Spitaleri D, Paolicelli D, Granata A, Zappia M, Patti F; SA.FE. study group.

PLoS One. 2017 Aug 1;12(8):e0180651. doi: 10.1371/journal.pone.0180651. eCollection 2017.

6.

Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis.

Tortorella C, Direnzo V, Ruggieri M, Zoccolella S, Mastrapasqua M, D'Onghia M, Paolicelli D, Cuonzo FD, Gasperini C, Trojano M.

Mult Scler. 2018 Jul;24(8):1039-1045. doi: 10.1177/1352458517711774. Epub 2017 May 24. Erratum in: Mult Scler. 2018 Dec 3;:1352458518819093.

PMID:
28537100
7.

Prognostic indicators in pediatric clinically isolated syndrome.

Iaffaldano P, Simone M, Lucisano G, Ghezzi A, Coniglio G, Brescia Morra V, Salemi G, Patti F, Lugaresi A, Izquierdo G, Bergamaschi R, Cabrera-Gomez JA, Pozzilli C, Millefiorini E, Alroughani R, Boz C, Pucci E, Zimatore GB, Sola P, Lus G, Maimone D, Avolio C, Cocco E, Sajedi SA, Costantino G, Duquette P, Shaygannejad V, Petersen T, Fernández Bolaños R, Paolicelli D, Tortorella C, Spelman T, Margari L, Amato MP, Comi G, Butzkueven H, Trojano M; Italian iMedWeb Registry and the MSBase Registry.

Ann Neurol. 2017 May;81(5):729-739. doi: 10.1002/ana.24938.

PMID:
28439957
8.

Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients.

Paolicelli D, Manni A, D'Onghia M, Direnzo V, Iaffaldano P, Zoccolella S, Di Lecce V, Tortorella C, Specchia G, Trojano M.

J Neuroimmunol. 2017 Feb 15;303:75-80. doi: 10.1016/j.jneuroim.2016.12.012. Epub 2016 Dec 21.

PMID:
28043652
9.

A rare association between multiple sclerosis and Charcot-Marie-Tooth type 1B.

Cortese R, Zoccolella S, Muglia M, Patitucci A, Scarafino A, Paolicelli D, Simone IL.

Brain Behav. 2016 Sep 25;6(12):e00580. doi: 10.1002/brb3.580. eCollection 2016 Dec.

10.

The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy.

Paolicelli D, Iannazzo S, Santoni L, Iaffaldano A, Di Lecce V, Manni A, Lavolpe V, Tortorella C, D'Onghia M, Direnzo V, Puma E, Trojano M.

PLoS One. 2016 Jul 8;11(7):e0159214. doi: 10.1371/journal.pone.0159214. eCollection 2016.

11.

The role of neutralizing antibodies to interferon-β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study.

Paolicelli D, Manni A, Iaffaldano A, Di Lecce V, D'Onghia M, Iaffaldano P, Trojano M.

Eur J Clin Pharmacol. 2016 Aug;72(8):1025-9. doi: 10.1007/s00228-016-2073-6. Epub 2016 Jun 1.

PMID:
27251359
12.

Predictors of long-term disability accrual in relapse-onset multiple sclerosis.

Jokubaitis VG, Spelman T, Kalincik T, Lorscheider J, Havrdova E, Horakova D, Duquette P, Girard M, Prat A, Izquierdo G, Grammond P, Van Pesch V, Pucci E, Grand'Maison F, Hupperts R, Granella F, Sola P, Bergamaschi R, Iuliano G, Spitaleri D, Boz C, Hodgkinson S, Olascoaga J, Verheul F, McCombe P, Petersen T, Rozsa C, Lechner-Scott J, Saladino ML, Farina D, Iaffaldano P, Paolicelli D, Butzkueven H, Lugaresi A, Trojano M; MSBase Study Group.

Ann Neurol. 2016 Jul;80(1):89-100. doi: 10.1002/ana.24682. Epub 2016 Jun 1.

PMID:
27145331
13.

Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study.

Paolicelli D, Cocco E, Di Lecce V, Direnzo V, Moiola L, Lanzillo R, Perini P, Malucchi S, Borriello G, Portaccio E, Panetta V, Fenu G, Sangalli F, Cacciaguerra L, Trojano M; TRACER Group.

Expert Opin Drug Deliv. 2016 Jun;13(6):799-805. doi: 10.1517/17425247.2016.1158161. Epub 2016 Mar 12.

PMID:
26922837
14.

Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.

Paolicelli D, Direnzo V, Manni A, D'Onghia M, Tortorella C, Zoccolella S, Di Lecce V, Iaffaldano A, Trojano M.

J Clin Pharmacol. 2016 Jul;56(7):845-51. doi: 10.1002/jcph.670. Epub 2015 Dec 30.

PMID:
26608223
15.

The Cost of Patients With Relapsing-Remitting Multiple Sclerosis Who Develop Neutralizing Antibodies While Treated With Interferon Beta.

Paolicelli D, Iannazzo S, Santoni L, D'Onghia M, Direnzo V, Iaffaldano A, Puma E, Di Lecce V, Trojano M.

Value Health. 2015 Nov;18(7):A754. doi: 10.1016/j.jval.2015.09.2925. Epub 2015 Oct 20. No abstract available.

16.

Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.

Iaffaldano P, Lucisano G, Pozzilli C, Brescia Morra V, Ghezzi A, Millefiorini E, Patti F, Lugaresi A, Zimatore GB, Marrosu MG, Amato MP, Bertolotto A, Bergamaschi R, Granella F, Coniglio G, Tedeschi G, Sola P, Lus G, Ferrò MT, Iuliano G, Corea F, Protti A, Cavalla P, Guareschi A, Rodegher M, Paolicelli D, Tortorella C, Lepore V, Prosperini L, Saccà F, Baroncini D, Comi G, Trojano M; Italian iMed-Web database.

Brain. 2015 Nov;138(Pt 11):3275-86. doi: 10.1093/brain/awv260. Epub 2015 Sep 11.

PMID:
26362907
17.

Predictors of disability worsening in clinically isolated syndrome.

Jokubaitis VG, Spelman T, Kalincik T, Izquierdo G, Grand'Maison F, Duquette P, Girard M, Lugaresi A, Grammond P, Hupperts R, Cabrera-Gomez J, Oreja-Guevara C, Boz C, Giuliani G, Fernández-Bolaños R, Iuliano G, Lechner-Scott J, Verheul F, van Pesch V, Petkovska-Boskova T, Fiol M, Moore F, Cristiano E, Alroughani R, Bergamaschi R, Barnett M, Slee M, Vella N, Herbert J, Shaw C, Saladino ML, Amato MP, Liew D, Paolicelli D, Butzkueven H, Trojano M.

Ann Clin Transl Neurol. 2015 May;2(5):479-91. doi: 10.1002/acn3.187. Epub 2015 Mar 27.

18.

Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study.

Paolicelli D, Manni A, Direnzo V, D'Onghia M, Tortorella C, Zoccolella S, Trojano M.

J Clin Pharmacol. 2015 Oct;55(10):1131-6. doi: 10.1002/jcph.519. Epub 2015 Jun 17.

PMID:
25903516
19.

Lesion load may predict long-term cognitive dysfunction in multiple sclerosis patients.

Patti F, De Stefano M, Lavorgna L, Messina S, Chisari CG, Ippolito D, Lanzillo R, Vacchiano V, Realmuto S, Valentino P, Coniglio G, Buccafusca M, Paolicelli D, D'Ambrosio A, Montella P, Brescia Morra V, Savettieri G, Alfano B, Gallo A, Simone I, Viterbo R, Zappia M, Bonavita S, Tedeschi G.

PLoS One. 2015 Mar 27;10(3):e0120754. doi: 10.1371/journal.pone.0120754. eCollection 2015.

20.

Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).

Clerico M, Schiavetti I, De Mercanti SF, Piazza F, Gned D, Brescia Morra V, Lanzillo R, Ghezzi A, Bianchi A, Salemi G, Realmuto S, Sola P, Vitetta F, Cavalla P, Paolicelli D, Trojano M, Sormani MP, Durelli L.

JAMA Neurol. 2014 Aug;71(8):954-60. doi: 10.1001/jamaneurol.2014.1200.

PMID:
24977406
21.

Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study.

Pecori C, Giannini M, Portaccio E, Ghezzi A, Hakiki B, Pastò L, Razzolini L, Sturchio A, De Giglio L, Pozzilli C, Paolicelli D, Trojano M, Marrosu MG, Patti F, Mancardi GL, Solaro C, Totaro R, Tola MR, De Luca G, Lugaresi A, Moiola L, Martinelli V, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.

BMC Neurol. 2014 May 26;14:114. doi: 10.1186/1471-2377-14-114.

22.

Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study.

Frisullo G, Calabrese M, Tortorella C, Paolicelli D, Ragonese P, Annovazzi P, Radaelli M, Malucchi S, Gallo A, Tomassini V, Nociti V, D'Onghia M, Lo Re V, Rodegher M, Solaro C, Gasperini C.

Mult Scler. 2014 Aug;20(9):1265-8. doi: 10.1177/1352458514521311. Epub 2014 Feb 10.

PMID:
24515732
23.

The MoSt Project--more steps in multiple sclerosis: a Delphi method consensus initiative for the evaluation of mobility management of MS patients in Italy.

Capra R, Battaglia MA, Gaudioso A, Lopes L, Paolicelli D, Paoloni M, Pozzilli C, Santilli V, Solaro C, Trojano M.

J Neurol. 2014 Mar;261(3):526-32. doi: 10.1007/s00415-013-7230-6. Epub 2014 Jan 22.

PMID:
24449060
24.

Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs.

Portaccio E, Ghezzi A, Hakiki B, Sturchio A, Martinelli V, Moiola L, Patti F, Mancardi GL, Solaro C, Tola MR, Pozzilli C, De Giglio L, Totaro R, Lugaresi A, De Luca G, Paolicelli D, Marrosu MG, Comi G, Trojano M, Amato MP; MS Study Group of the Italian Neurological Society.

J Neurol Neurosurg Psychiatry. 2014 Aug;85(8):845-50. doi: 10.1136/jnnp-2013-306054. Epub 2014 Jan 8.

PMID:
24403285
25.

Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group.

Bertolotto A, Capobianco M, Amato MP, Capello E, Capra R, Centonze D, Di Ioia M, Gallo A, Grimaldi L, Imberti L, Lugaresi A, Mancinelli C, Marrosu MG, Moiola L, Montanari E, Romano S, Musu L, Paolicelli D, Patti F, Pozzilli C, Rossi S, Salvetti M, Tedeschi G, Tola MR, Trojano M, Zaffaroni M, Malucchi S; Italian Multiple Sclerosis Study group.

Neurol Sci. 2014 Feb;35(2):307-16. doi: 10.1007/s10072-013-1616-1. Epub 2013 Dec 29. Erratum in: Neurol Sci. 2014 Oct;35(10):1645-6. Troiano, Maria [corrected to Trojano, Maria].

PMID:
24374787
26.

Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study.

Lavorgna L, Bonavita S, Ippolito D, Lanzillo R, Salemi G, Patti F, Valentino P, Coniglio G, Buccafusca M, Paolicelli D, d'Ambrosio A, Bresciamorra V, Savettieri G, Zappia M, Alfano B, Gallo A, Simone I, Tedeschi G.

Mult Scler. 2014 Feb;20(2):220-6. doi: 10.1177/1352458513494958. Epub 2013 Jul 9.

PMID:
23838177
27.

The impact of neutralizing antibodies on the risk of disease worsening in interferon β-treated relapsing multiple sclerosis: a 5 year post-marketing study.

Paolicelli D, D'Onghia M, Pellegrini F, Direnzo V, Iaffaldano P, Lavolpe V, Trojano M.

J Neurol. 2013 Jun;260(6):1562-8. doi: 10.1007/s00415-012-6829-3. Epub 2013 Feb 17.

PMID:
23417273
28.

Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study.

Pastò L, Portaccio E, Ghezzi A, Hakiki B, Giannini M, Razzolini L, Piscolla E, De Giglio L, Pozzilli C, Paolicelli D, Trojano M, Marrosu MG, Patti F, La Mantia L, Mancardi GL, Solaro C, Totaro R, Tola MR, Di Tommaso V, Lugaresi A, Moiola L, Martinelli V, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.

BMC Neurol. 2012 Dec 31;12:165. doi: 10.1186/1471-2377-12-165.

29.

Geographical variations in sex ratio trends over time in multiple sclerosis.

Trojano M, Lucchese G, Graziano G, Taylor BV, Simpson S Jr, Lepore V, Grand'maison F, Duquette P, Izquierdo G, Grammond P, Amato MP, Bergamaschi R, Giuliani G, Boz C, Hupperts R, Van Pesch V, Lechner-Scott J, Cristiano E, Fiol M, Oreja-Guevara C, Saladino ML, Verheul F, Slee M, Paolicelli D, Tortorella C, D'Onghia M, Iaffaldano P, Direnzo V, Butzkueven H; MSBase Study Group and the New Zealand MS Prevalence Study Group.

PLoS One. 2012;7(10):e48078. doi: 10.1371/journal.pone.0048078. Epub 2012 Oct 25.

30.

Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study.

Giannini M, Portaccio E, Ghezzi A, Hakiki B, Pastò L, Razzolini L, Piscolla E, De Giglio L, Pozzilli C, Paolicelli D, Trojano M, Marrosu MG, Patti F, La Mantia L, Mancardi G, Solaro C, Totaro R, Tola MR, De Luca G, Lugaresi A, Moiola L, Martinelli V, Comi G, Amato MP.

BMC Neurol. 2012 Oct 22;12:124. doi: 10.1186/1471-2377-12-124.

31.

Low serum urate levels are associated to female gender in multiple sclerosis patients.

Zoccolella S, Tortorella C, Iaffaldano P, Direnzo V, D'Onghia M, Luciannatelli E, Paolicelli D, Livrea P, Trojano M.

PLoS One. 2012;7(7):e40608. doi: 10.1371/journal.pone.0040608. Epub 2012 Jul 27.

32.

Immunomodulatory therapies delay disease progression in multiple sclerosis.

Bergamaschi R, Quaglini S, Tavazzi E, Amato MP, Paolicelli D, Zipoli V, Romani A, Tortorella C, Portaccio E, D'Onghia M, Garberi F, Bargiggia V, Trojano M.

Mult Scler. 2016 Nov;22(13):1732-1740. Epub 2012 May 31.

PMID:
22653657
33.

Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.

Iaffaldano P, Viterbo RG, Paolicelli D, Lucchese G, Portaccio E, Goretti B, Direnzo V, D'Onghia M, Zoccolella S, Amato MP, Trojano M.

PLoS One. 2012;7(4):e35843. doi: 10.1371/journal.pone.0035843. Epub 2012 Apr 25.

34.

Elevated plasma homocysteine levels in patients with multiple sclerosis are associated with male gender.

Zoccolella S, Tortorella C, Iaffaldano P, Direnzo V, D'Onghia M, Paolicelli D, Livrea P, Trojano M.

J Neurol. 2012 Oct;259(10):2105-10. doi: 10.1007/s00415-012-6464-z. Epub 2012 Mar 16.

PMID:
22421956
35.

A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy.

Annovazzi P, Tomassini V, Bodini B, Boffa L, Calabrese M, Cocco E, Cordioli C, De Luca G, Frisullo G, Gallo A, Malucchi S, Paolicelli D, Pesci I, Radaelli M, Ragonese P, Roccatagliata L, Tortorella C, Vercellino M, Zipoli V, Gasperini C, Rodegher M, Solaro C.

Neurol Sci. 2013 Feb;34(2):197-203. doi: 10.1007/s10072-012-0981-5. Epub 2012 Mar 11.

PMID:
22407022
36.

Breastfeeding is not related to postpartum relapses in multiple sclerosis.

Portaccio E, Ghezzi A, Hakiki B, Martinelli V, Moiola L, Patti F, La Mantia L, Mancardi GL, Solaro C, Tola MR, Pozzilli C, De Giglio L, Totaro R, Lugaresi A, De Luca G, Paolicelli D, Marrosu MG, Comi G, Trojano M, Amato MP; MS Study Group of the Italian Neurological Society.

Neurology. 2011 Jul 12;77(2):145-50. doi: 10.1212/WNL.0b013e318224afc9. Epub 2011 Jul 6.

PMID:
21734184
37.

Natural history of multiple sclerosis: have available therapies impacted long-term prognosis?

Trojano M, Paolicelli D, Tortorella C, Iaffaldano P, Lucchese G, Di Renzo V, D'Onghia M.

Neurol Clin. 2011 May;29(2):309-21. doi: 10.1016/j.ncl.2010.12.008. Review.

PMID:
21439443
38.

Age-related changes of serum N-acetyl-aspartate in healthy controls.

Ruggieri M, Tortorella C, Ceci E, Paolicelli D, Solfrizzi V, Di Bitonto G, Pica C, Mastrapasqua M, Livrea P, Trojano M.

Age Ageing. 2011 May;40(3):391-5. doi: 10.1093/ageing/afr021. Epub 2011 Mar 20. No abstract available.

PMID:
21422012
39.

Multiple sclerosis in Italy: cost-of-illness study.

Patti F, Amato MP, Trojano M, Solaro C, Pappalardo A, Zipoli V, Portaccio E, Paolicelli D, Paolillo A, Mennini FS, Marcellusi A, Ricci C, Battaglia MA.

Neurol Sci. 2011 Oct;32(5):787-94. doi: 10.1007/s10072-011-0499-2. Epub 2011 Mar 16.

PMID:
21409509
40.

Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis.

Amato MP, Portaccio E, Ghezzi A, Hakiki B, Zipoli V, Martinelli V, Moiola L, Patti F, La Mantia L, Mancardi GL, Solaro C, Tola MR, Pozzilli C, De Giglio L, Totaro R, Lugaresi A, Di Tommaso V, Paolicelli D, Marrosu MG, Comi G, Pellegrini F, Trojano M; MS Study Group of the Italian Neurological Society.

Neurology. 2010 Nov 16;75(20):1794-802. doi: 10.1212/WNL.0b013e3181fd62bb.

PMID:
21079181
41.

observational studies: propensity score analysis of non-randomized data.

Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Di Renzo V.

Int MS J. 2009 Sep;16(3):90-7.

PMID:
19878631
42.

Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.

Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Zipoli V, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, Cavalla P, Lepore V, Livrea P, Comi G, Amato MP; Italian Multiple Sclerosis Database Network (MSDN) Group.

Ann Neurol. 2009 Oct;66(4):513-20. doi: 10.1002/ana.21757.

PMID:
19847899
43.

Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis.

Paolicelli D, Direnzo V, Trojano M.

Biologics. 2009;3:369-76. Epub 2009 Jul 13.

44.

Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.

Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Portaccio E, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, Cavalla P, Iaffaldano P, Direnzo V, D'Onghia M, Lepore V, Livrea P, Comi G, Amato MP; Italian Multiple Sclerosis Database Network Group.

J Neurol Sci. 2009 Nov 15;286(1-2):109-13. doi: 10.1016/j.jns.2009.06.036. Epub 2009 Jul 16.

PMID:
19615696
45.

Postmarketing evidence of disease-modifying drugs in multiple sclerosis.

Trojano M, Paolicelli D, Fuiani A, Pellegrini F, Iaffaldano P, Direnzo V, D'Onghia M.

Neurol Sci. 2008 Sep;29 Suppl 2:S225-6. doi: 10.1007/s10072-008-0944-z. Review.

PMID:
18690499
46.

Variations of the perforin gene in patients with multiple sclerosis.

Cappellano G, Orilieri E, Comi C, Chiocchetti A, Bocca S, Boggio E, Bernardone IS, Cometa A, Clementi R, Barizzone N, D'Alfonso S, Corrado L, Galimberti D, Scarpini E, Guerini FR, Caputo D, Paolicelli D, Trojano M, Figà-Talamanca L, Salvetti M, Perla F, Leone M, Monaco F, Dianzani U.

Genes Immun. 2008 Jul;9(5):438-44. doi: 10.1038/gene.2008.35. Epub 2008 May 22.

PMID:
18496551
47.

New natural history of interferon-beta-treated relapsing multiple sclerosis.

Trojano M, Pellegrini F, Fuiani A, Paolicelli D, Zipoli V, Zimatore GB, Di Monte E, Portaccio E, Lepore V, Livrea P, Amato MP.

Ann Neurol. 2007 Apr;61(4):300-6.

PMID:
17444502
48.

Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score.

Bergamaschi R, Quaglini S, Trojano M, Amato MP, Tavazzi E, Paolicelli D, Zipoli V, Romani A, Fuiani A, Portaccio E, Berzuini C, Montomoli C, Bastianello S, Cosi V.

J Neurol Neurosurg Psychiatry. 2007 Jul;78(7):757-9. Epub 2007 Jan 12.

49.

The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosis.

Trojano M, Russo P, Fuiani A, Paolicelli D, Di Monte E, Granieri E, Rosati G, Savettieri G, Comi G, Livrea P; MSDN Study Group.

Mult Scler. 2006 Oct;12(5):578-85.

PMID:
17086903
50.

Italian Multiple Sclerosis Database Network.

Trojano M, Paolicelli D, Lepore V, Fuiani A, Di Monte E, Pellegrini F, Russo P, Livrea P, Comi G; Italian MSDN Group.

Neurol Sci. 2006 Sep;27 Suppl 5:S358-61.

PMID:
16998720

Supplemental Content

Loading ...
Support Center